Results 61 to 70 of about 30,793 (265)

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Neoantigen vaccine: an emerging tumor immunotherapy

Molecular Cancer, 2019
Genetic instability of tumor cells often leads to the occurrence of a large number of mutations, and expression of non-synonymous mutations can produce tumor-specific antigens called neoantigens.
Miao Peng, Yongzhen Mo, Yian Wang, Pan Wu, Yijie Zhang, Fang Xiong, Can Guo, Xu Wu, Yong Li, Xiaoling Li, Guiyuan Li, Wei Xiong, Zhaoyang Zeng   +12 more
doaj   +1 more source

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy

OncoImmunology, 2021
Genetic mutations lead to the production of mutated proteins from which peptides are presented to T cells as cancer neoantigens. Evidence suggests that T cells that target neoantigens are the main mediators of effective cancer immunotherapies.
Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K. Chan, John W. Kappler, Yu Zhou, Eric Tran, Philippa Marrack, Lei Yin   +12 more
doaj   +1 more source

The role of neoantigens in tumor immunotherapy

Biomedicine & Pharmacotherapy, 2022
Tumor neoantigens are aberrant polypeptides produced by tumor cells as a result of genomic mutations. They are also tumor-specific antigens (TSA). Neoantigens are more immunogenic than tumor-related antigens and do not induce autoimmunity. Based on the rapid development of bioinformatics and the continuous update of sequencing technology, cancer ...
Shengwen, Shang, Yongjie, Zhao, Kaiqiang, Qian, Yuexuan, Qin, Xinyi, Zhang, Tianyue, Li, Lidong, Shan, Meili, Wei, Jun, Xi, Bikui, Tang   +9 more
openaire   +2 more sources

DataSheet_7_A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.pdf

, 2022
Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells. With high specificity and immunogenicity, neoantigens are considered as an ideal target for immunotherapy.
Lijian Zhao (5734019), Hai-Xi Sun (9499079), Songming Liu (12267134), Si Zhou (669724)   +3 more
core   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Modeling Tumor Neoantigens for Predicting Patients' Clinical Outcomes [PDF]

Tumor neoantigens are critical targets of the host antitumor immune response and their presence play an important role in affecting tumor progressions and immunotherapy treatment response.
Lu, Tianshi
core   +1 more source

Neoantigens in cancer immunotherapy: quantity vs. quality

Molecular Oncology, 2023
Traditional immunotherapies provide clinical benefits to only a few patients with solid tumors, highlighting the urgent need for more effective approaches.
Yochai Wolf, Yardena Sameuls
doaj   +1 more source

FusionNeoAntigen: a resource of fusion gene-specific neoantigens [PDF]

, 2023
Among the diverse sources of neoantigens (i.e. single-nucleotide variants (SNVs), insertions or deletions (Indels) and fusion genes), fusion gene-derived neoantigens are generally more immunogenic, have multiple targets per mutation and are more widely ...
Ruihan Luo, Chengyuan Yang, Zhou, Xiaobo, Wen, Jianguo, Luo, Ruihan, Himansu Kumar, Jianguo Wen, Yang, Chengyuan, Kumar, Himansu, Kim, Pora, Pora Kim, Xiaobo Zhou   +11 more
core   +1 more source

Engineering Microbial Particles for Next‐Generation Biomedical Platforms

Advanced Science, EarlyView.
Microbe‐derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus‐like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a ...
Yuting Li, Yunjie Lu, Ziyan Huang, Jianjiang Chen, Yanbin Liu, Lei Qin, Chao Wang, Yumin Wu   +7 more
wiley   +1 more source